Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Immunization Information Systems (IIS)








Fall Season Respiratory Vaccine Codes						Print
																Related Pages
										**On This Page**
			Fall 2023 COVID-19 Vaccine Codes and CrosswalksOther COVID-19 Vaccine Related Codes and LinksRespiratory Syncytial Virus (RSV) Codes and Crosswalks2023/2024 Seasonal Influenza Codes and Crosswalkemail_03Get Email Updates	To receive email updates about this page, enter your email address:		Email Address			What's this?				SubmitFall Season Respiratory Vaccine Codes
The current Fall vaccine code and crosswalk tables for COVID-19, RSV, and Influenza are provided in the following summary tables.
Fall 2023 COVID-19 Vaccine Codes and Crosswalks
The following table provides a preview and summary of the vaccine codes and crosswalks that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines.
Note: *Codes in the following table are effective and published in the full vaccine code sets only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA). Additional code details and fields values are included in the vaccine code sets once published.*
Download the Fall 2023 COVID-19 Vaccine Code Crosswalk tableFALL 2023 COVID-19 CODES AND CROSSWALK
Manufacturer (MVX)
Product Label Tradename (*)
CVX Code
CVX Term Description
CVX Short Description
NDC Virus Strain
UoS NDC10
UoS NDC11
Packaging
UoU NDC10
UoU NDC11
Age Cohort;
Presentation
CPT Code
CPT DescriptionPfizer
(PFR)
COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula)
309
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL
SARS-CoV-2 virus strain Omicron XBB.1.5
0069-2362-10
00069-2362-10
CARTON, 10 SINGLE-DOSE VIALS
0069-2362-01
00069-2362-01
Ages 12 years and older;
VIAL, SINGLE-DOSE, 30 mcg/0.3 mL
91320
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular usePfizer
(PFR)
COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula), no freeze formulation
309
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL
SARS-CoV-2 virus strain Omicron XBB.1.5
0069-2377-10 00069-2377-10
CARTON, 10 PRE-FILLED GLASS SYRINGES
0069-2377-01 00069-2377-01
Ages 12 years and older;
GLASS SYRINGE, SINGLE-DOSE, 30 mcg/0.3 mL – DO NOT FREEZE
91320
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular usePfizer
(PFR)
COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula)
309
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL
SARS-CoV-2 virus strain Omicron XBB.1.5
0069-2392-10
00069-2392-10
CARTON, 10 PRE-FILLED PLASTIC SYRINGES
0069-2392-01
00069-2392-01
Ages 12 years and older;
PLASTIC SYRINGE, PRE-FILLED, 30 mcg/0.3 mL
91320
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular usePfizer
(PFR)
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula)
310
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL
SARS-CoV-2 virus strain Omicron XBB.1.5
59267-4331-2
59267-4331-02
CARTON, 10 SINGLE-DOSE VIALS
59267-4331-1
59267-4331-01
Ages 5 through 11 years;
VIAL, SINGLE-DOSE, 10 mcg/0.3 mL
91319
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular usePfizer
(PFR)
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula)
308
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose
COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL
SARS-CoV-2 virus strain Omicron XBB.1.5
59267-4315-2
59267-4315-02
CARTON, 10 MULTI-DOSE VIALS
59267-4315-1
59267-4315-01
Ages 6 months through 4 years;
VIAL, MULTI-DOSE, 3 DOSES, 3mcg / 0.3 mL AFTER DILUTION
91318
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular useNovavax
(NVX)
Novavax COVID-19 Vaccine, Adjuvanted
313
SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose
COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL
SARS-CoV-2 virus strain Omicron XBB.1.5
80631-105-02
80631-0105-02
CARTON, 2 MULTI-DOSE VIALS
80631-105-01
80631-0105-01
Ages 12 years and older;
VIAL, MULTI-DOSE, 5 DOSES, 5 mcg/0.5 mL
91304
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular useModerna
(MOD)
Spikevax
312
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL
SARS-CoV-2 virus strain Omicron XBB.1.5
80777-102-95
80777-0102-95
CARTON, 10 SINGLE-DOSE VIALS
80777-102-04
80777-0102-04
Ages 12 years and older;
VIAL, SINGLE-DOSE, 50 mcg/0.5 mL
91322
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular useModerna
(MOD)
Spikevax
312
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL
SARS-CoV-2 virus strain Omicron XBB.1.5
80777-102-96
80777-0102-96
CARTON, 10 PRE-FILLED SYRINGES
80777-102-01
80777-0102-01
Ages 12 years and older;
SYRINGE, PRE-FILLED, 50 mcg/0.5 mL
91322
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular useModerna
(MOD)
Spikevax
312
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL
SARS-CoV-2 virus strain Omicron XBB.1.5
80777-102-93
80777-0102-93
CARTON, 10 BLISTER-SEALED PRE-FILLED SYRINGES
80777-102-01
80777-0102-01
Ages 12 years and older;
SYRINGE, PRE-FILLED, 50 mcg/0.5 mL
91322
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular useModerna
(MOD)
Moderna COVID-19 Vaccine
311
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose
COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL
SARS-CoV-2 virus strain Omicron XBB.1.5
80777-287-92
80777-0287-92
CARTON, 10 SINGLE-DOSE VIALS
80777-287-07
80777-0287-07
Ages 6 months through 11 years;
VIAL, SINGLE-DOSE, 25 mcg/0.25 mL
91321
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use(*) Product Label Tradename: If the manufacturer name is included in the tradename, the vaccine product is to be provided under Emergency Use Authorization (EUA), once FDA EUA issuance is received. Other tradenames are for vaccine products to be provided under BLA licensure, once approved.Other COVID-19 Vaccine Related Codes and Links
Information regarding currently active EUA Recipient and Caregiver Fact Sheet URLs and Codes can be found here.
Registered users can access COVID-19 vaccine lot numbers and expiration dates provided to CDC by the vaccine manufacturer.
Information regarding **Previous**COVID-19 pandemic Emergency Use Authorization (EUA) and BLA codes and crosswalks can be found here.Respiratory Syncytial Virus (RSV) Codes and Crosswalks
The following table includes the RSV codes and crosswalks included in the CDC IIS Vaccine Code Sets. Note that the CPT codes shown are not mapped to the NDC codes, but are mapped to the CVX codes shown. CPT codes provided in the vaccine code sets are to assist with code categorizations and are not intended to represent billable codes.
Download the RSV Crosswalk tableRespiratory Syncytial Virus (RSV) Vaccine Codes Fall 2023
CVX Code
CVX Description
Sale Proprietary Name
Sale Labeler
MVX Code
Unit of Sale NDC11
Unit of Use NDC11
Presentation
CPT Code
CPT Description303
Respiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative free
Arexvy
GlaxoSmithKline Biologicals SA
SKB
58160-0848-11
58160-0723-03
VIAL, 0.5 mL, reconstituted
90679
Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use305
Respiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative free
Abrysvo
Pfizer Laboratories Div Pfizer Inc
PFR
00069-0344-01
00069-0344-05
00069-0344-10
00069-0207-01
VIAL, 0.5 mL, reconstituted
90678
Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular useRespiratory Syncytial Virus (RSV) Monoclonal Antibody Codes Fall 2023 (*)
CVX Code
CVX Description
Sale Proprietary Name
Sale Labeler
MVX Code
Unit of Sale NDC11
Unit of Use NDC11
Presentation
CPT Code
CPT Description306
Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 months
BEYFORTUS
Sanofi Pasteur Inc.
PMC
49281-0575-15
49281-0575-00
SYRINGE, 0.5 mL
90380
Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use307
Respiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 months
BEYFORTUS
Sanofi Pasteur Inc.
PMC
49281-0574-15
49281-0574-88
SYRINGE, 1 mL
90381
Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use(*) The BEYFORTUS nirsevimab monoclonal antibody codes are included in the vaccine code set in a manner similar to regular vaccines to enable reporting or other program data exchange in accordance with ACIP and CDC guidelines.Respiratory Syncytial Virus (RSV) Unspecified Codes
CVX Code
CVX Description
CVX Note314
Respiratory syncytial virus (RSV) vaccine, unspecified
Unspecified, for historic records where the specific vaccine administered is not known315
Respiratory syncytial virus (RSV) monoclonal antibody (MAB), unspecified
Unspecified, for historic records where the specific RSV MAB administered is not known304
Respiratory syncytial virus (RSV), unspecified
Unspecified, for historic records where it is not known if RSV vaccine or RSV MAB was administered
Guidance relating to RSV vaccines can be found at Home page for MMWR | MMWR (cdc.gov)
On July 17, 2023, the Food and Drug Administration licensed Nirsevimab (Beyfortus), a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) in infants and young children. It is anticipated that the Advisory Committee on Immunization Practices (ACIP) will vote on potential recommendations for use of this product and its inclusion in the Vaccines for Children (VFC) program at the August 3rd ACIP meeting.
New codes listed above have been added in anticipation of potential recommendations.  More information to support integration into VFC, as well as details around vaccine codes, Clinical Decision Support for Immunization (CDSi), and any data collection requirements will be published as they become available.2023/2024 Seasonal Influenza Codes and Crosswalk
This new format includes all seasonal influenza vaccines for the 2023/2024 season in a single Excel crosswalk table that provides the CVX, MVX, NDC Unit of Sale, NDC Unit of Use, and CPT (*) codes for each vaccine.
(*) Please note that the CPT codes shown for each vaccine crosswalk are not mapped to the NDC codes, but are mapped to the CVX codes shown.  These are reference CPT codes for vaccine categorization and are not intended to represent billable codes.
Download the Seasonal Influenza Crosswalk tableInfluenza Vaccines for Season 2023/2024 (Northern Hemisphere)
CVX Code
CVX Short Description
Sale Proprietary Name
Sale Labeler
MVX Code
Unit of Sale NDC11
Unit of Use NDC11
Presentation
CPT Code
CPT Description149
influenza, live, intranasal, quadrivalent
FluMist Quadrivalent
MedImmune, LLC
MED
66019-0310-10
66019-0310-01
APPLICATOR 0.2 mL
90672
Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use150
Influenza, injectable, quadrivalent, preservative free
Afluria Quadrivalent
Seqirus PTY LTD.
SEQ
33332-0323-03
33332-0323-04
SYRINGE, 0.5 mL
90686
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use150
influenza, injectable, quadrivalent, preservative free
FLUARIX QUADRIVALENT
GlaxoSmithKline Biologicals SA
SKB
58160-0909-52
58160-0909-41
SYRINGE, 0.5 mL
90686
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use150
influenza, injectable, quadrivalent, preservative free
Flulaval Quadrivalent
ID Biomedical Corporation of Quebec
IDB
19515-0814-52
19515-0814-41
SYRINGE, 0.5 mL
90686
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use150
influenza, injectable, quadrivalent, preservative free
Fluzone Quadrivalent Northern Hemisphere
Sanofi Pasteur Inc.
PMC
49281-0423-50
49281-0423-88
SYRINGE, 0.5 mL
90686
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use158
influenza, injectable, quadrivalent, contains preservative
Afluria Quadrivalent
Seqirus PTY LTD.
SEQ
33332-0423-10
33332-0423-11
VIAL, 5 mL, MULTI-DOSE
90687
Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use90688
Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use158
influenza, injectable, quadrivalent
Fluzone Quadrivalent Northern Hemisphere
Sanofi Pasteur Inc.
PMC
49281-0639-15
49281-0639-78
VIAL, 5 mL, MULTI-DOSE
90687
Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use90688
Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use171
Influenza, injectable, MDCK, preservative free, quadrivalent
Flucelvax Quadrivalent
Seqirus Inc.
SEQ
70461-0323-03
70461-0323-04
SYRINGE, 0.5 mL
90674
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use185
influenza, recombinant, quadrivalent,injectable, preservative free
Flublok Quadrivalent Northern Hemisphere
Sanofi Pasteur Inc.
PMC
49281-0723-10
49281-0723-88
SYRINGE, 0.5 mL
90682
Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use186
Influenza, injectable, MDCK, quadrivalent, preservative
Flucelvax Quadrivalent
Seqirus Inc.
SEQ
70461-0423-10
70461-0423-11
VIAL, 5 mL, MULTI-DOSE
90756
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use197
influenza, high-dose, quadrivalent
Fluzone High-Dose Quadrivalent Northern Hemisphere
Sanofi Pasteur Inc.
PMC
49281-0123-65
49281-0123-88
SYRINGE, 0.7 mL
90662
Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use205
Influenza vaccine, quadrivalent, adjuvanted
FLUAD QUADRIVALENT
Seqirus, Inc.
SEQ
70461-0123-03
70461-0123-04
SYRINGE, 0.5 ml
90694
Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular useSouthern Hemisphere 2023 Influenza Season
CVX Code
CVX Short Description
Sale Proprietary Name
Sale Labeler
MVX Code
Unit of Sale NDC11
Unit of Use NDC11
Presentation
CPT Code
CPT Description200
influenza, Southern Hemisphere, pediatric, preservative free
FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE
Sanofi Pasteur Inc.
PMC
NA
NA
SYRINGE, 0.25 mL
NA
NA201
influenza, Southern Hemisphere, preservative free
FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE
Sanofi Pasteur Inc.
PMC
49281-0323-50
49281-0323-88
SYRINGE, 0.5 mL
NA
NA202
influenza, Southern Hemisphere, quadrivalent, with preservative
FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE
Sanofi Pasteur Inc.
PMC
49281-0355-15
49281-0355-78
VIAL, MULTI-DOSE, 5 mL
NA
NA231
influenza, Southern Hemisphere, high-dose, quadrivalent
FLUZONE High-Dose Quadrivalent Southern Hemisphere
Sanofi Pasteur Inc.
PMC
49281-0379-50
49281-0379-88
SYRINGE, .7 mL
NA
NATop of Page
							
					
							Last Reviewed:  September 5, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeIIS Home
About IIS
Functional Standardsplus icon
Version 4.1
Core Data Elementsplus icon
Core Data Elements For IIS Functional Standards v4.0
Historical Core Data Elements
Data Code Setsplus icon
CVX
CVX Mapped to Vaccine Groups
CVX Mapped to VIS
MVX
Product Name Mapped to CVX/MVX
NDC Crosswalk Tables
VIS Barcode Lookup Table
VIS URL Table
CPT Mapped to CVX
Fall Season Respiratory Vaccine Codes
IIS Technical Guidanceplus icon
HL7
Transport (SOAP)
Deduplication
Clinical Decision Support for Immunization (CDSi)plus icon
CDSi Training Material
IZ Gatewayplus icon
Overview
Information Sheet
Awardee Forum Q&As
Meaningful Use
Vaccine 2D Barcodesplus icon
Vaccine 2D Barcoding for Manufacturers
Vaccines Shipping with 2D Barcodes
Vaccine 2D Barcode Scanning for Vendors
Vaccine 2D Barcode Scanning Initiatives
Vaccine 2D Barcode Scanning Implementation Toolkit
CDC IIS Activitiesplus icon
MIROW
NIS-IIS Collaboration
Sentinel Sites
IIS Strategic Planplus icon
2018-2020
2014-2017
Contacts for IIS Immunization Records
IIS Policy and Legislation
IIS Annual Report (IISAR)plus icon
Overview
Participation Rates and Maps
MMWR Articles on Annual Report Data
IISAR Survey Data
IIS Training
Resources & Reference Materialsplus icon
Acronyms
Conferences & Events
Frequently Asked Questions
Functional Standards Resource Guide
Partner Organizations
Publications
Sustainability Resources National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
1600 Clifton Road NE, Building 24
Mailstop A-19
Atlanta, GA 30333
iisinfo@cdc.gov
 Vaccines & ImmunizationsCDC Meaningful UseVaccine Tracking System (VTrckS)Vaccines for Children Program (VFC)Vaccine Management Business Improvement Project (VMBIP)Comprehensive Clinic Assessment Software Application (CoCASA)


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue